GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipocine Inc (NAS:LPCN) » Definitions » Cyclically Adjusted PB Ratio

Lipocine (Lipocine) Cyclically Adjusted PB Ratio : 0.32 (As of May. 20, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Lipocine Cyclically Adjusted PB Ratio?

As of today (2024-05-20), Lipocine's current share price is $6.37. Lipocine's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $20.04. Lipocine's Cyclically Adjusted PB Ratio for today is 0.32.

The historical rank and industry rank for Lipocine's Cyclically Adjusted PB Ratio or its related term are showing as below:

LPCN' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.1   Med: 0.31   Max: 1.48
Current: 0.3

During the past years, Lipocine's highest Cyclically Adjusted PB Ratio was 1.48. The lowest was 0.10. And the median was 0.31.

LPCN's Cyclically Adjusted PB Ratio is ranked better than
79.17% of 648 companies
in the Biotechnology industry
Industry Median: 1.725 vs LPCN: 0.30

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Lipocine's adjusted book value per share data for the three months ended in Mar. 2024 was $4.507. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $20.04 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Lipocine Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Lipocine's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipocine Cyclically Adjusted PB Ratio Chart

Lipocine Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.79 0.29 0.13

Lipocine Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.20 0.13 0.13 0.26

Competitive Comparison of Lipocine's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Lipocine's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lipocine's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipocine's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Lipocine's Cyclically Adjusted PB Ratio falls into.



Lipocine Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Lipocine's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=6.37/20.04
=0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lipocine's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Lipocine's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=4.507/131.7762*131.7762
=4.507

Current CPI (Mar. 2024) = 131.7762.

Lipocine Quarterly Data

Book Value per Share CPI Adj_Book
201406 45.000 100.560 58.969
201409 39.858 100.428 52.300
201412 35.024 99.070 46.587
201503 31.394 99.621 41.527
201506 48.695 100.684 63.733
201509 43.096 100.392 56.569
201512 39.121 99.792 51.659
201603 33.327 100.470 43.711
201606 28.652 101.688 37.130
201609 26.061 101.861 33.715
201612 23.964 101.863 31.001
201703 21.956 102.862 28.128
201706 20.772 103.349 26.486
201709 19.080 104.136 24.144
201712 15.174 104.011 19.225
201803 13.328 105.290 16.681
201806 11.096 106.317 13.753
201809 9.372 106.507 11.596
201812 7.380 105.998 9.175
201903 8.683 107.251 10.669
201906 6.773 108.070 8.259
201909 5.098 108.329 6.201
201912 2.839 108.420 3.451
202003 2.328 108.902 2.817
202006 3.624 108.767 4.391
202009 3.755 109.815 4.506
202012 3.724 109.897 4.465
202103 8.162 111.754 9.624
202106 6.883 114.631 7.912
202109 6.318 115.734 7.194
202112 8.774 117.630 9.829
202203 8.147 121.301 8.851
202206 7.662 125.017 8.076
202209 7.231 125.227 7.609
202212 6.844 125.222 7.202
202303 6.138 127.348 6.351
202306 5.454 128.729 5.583
202309 4.229 129.860 4.291
202312 3.832 129.419 3.902
202403 4.507 131.776 4.507

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Lipocine  (NAS:LPCN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Lipocine Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Lipocine's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lipocine (Lipocine) Business Description

Industry
Traded in Other Exchanges
N/A
Address
675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107.
Executives
Mahesh V. Patel director, officer: President and CEO C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Richard Dana Ono director 18 SPRING ROAD, CONCORD MA 01742
Spyridon Papapetropoulos director C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 1000, EMERYVILLE CA 94608
George Nomikos officer: Chief Medical Officer 675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY UT 84108
Krista Fogarty officer: Principal Accounting Officer 675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY UT 84108
Jill M. Jene director 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
John W. Higuchi director C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Morgan R Brown officer: EVP and CFO 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Stephen A Hill director 50 AVENUE GENERAL DE GAULLE, BRUXELLES C9 9999999999
Jeffrey Arvin Fink director 2265 MORNING STAR DRIVE, PARK CITY UT 84060
Gregory Brooks Bass officer: EVP and Chief Commercial Offic 3228 BROOKSIDE DRIVE, FURLONG PA 18925
Jyrki Mattila officer: Chief Business Officer AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Srinivasan Venkateshwaran officer: CTO and VP RandD C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Robert K. Merrell officer: VP Finance C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Gerald T Simmons officer: VP Corp Business Development 837 4TH AVE, SALT LAKE CITY UT 84103